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Abstract
Background: Bardet–Biedl syndrome (BBS) is a rare inherited multisystemic disorder with autosomal recessive or
complex digenic triallelic inheritance. There is currently no treatment for BBS, but some morbidities can be managed.
Accurate molecular diagnosis is often crucial for the definition of appropriate patient management and for the
development of a potential personalized therapy.
Methods: We developed a next-generation-sequencing (NGS) protocol for the screening of the 18 most frequently
mutated genes to define the genotype and clarify the mutation spectrum of a cohort of 20 BBS Italian patients.
Results: We defined the causative variants in 60% of patients; four of those are novel. 33% of patients also harboured
variants in additional gene/s, suggesting possible oligogenic inheritance. To explore the function of different genes, we
looked for correlations between genotype and phenotype in our cohort. Hypogonadism was more frequently
detected in patients with variants in BBSome proteins, while renal abnormalities in patients with variations in
BBSome chaperonin genes.
Conclusions: NGS is a powerful tool that can help understanding BBS patients’ phenotype through the identification
of mutations that could explain differences in phenotype severity and could provide insights for the development of
targeted therapy. Furthermore, our results support the existence of additional BBS loci yet to be identified.
Keywords: NGS, Bardet-Biedl syndrome, Genetic diagnosis; triallelic inheritance
Background
Bardet-Biedl syndrome (BBS) is a rare inherited, clinically
and genetically heterogeneous, multisystemic ciliopathy
with various primary and secondary clinical manifestations
[1]. Although the common postaxial hexadactyly is evi-
dent at birth, in absence of a family history the diagnosis
is usually made after the manifestation of ocular involve-
ment. The main features are: retinal dystrophy (cone-rod
type) often leading to blindness, upper and lower limbs
polydactyly, early-onset truncal obesity, intellectual im-
pairment, hypogonadism and renal abnormalities. A num-
ber of secondary features is also described [1]. Life
expectancy can be reduced, mainly due to renal failure [2].
Twenty-one different loci (BBS1-BBS21) have been
associated with this syndrome. The genes mostly code
for proteins forming the core BBSome complex
(BBS1, BBS2, BBS4, BBS5, BBS7, BBS8 and BBS9) or
part of a BBS chaperone complex (BBS6, BBS10 and
BBS12) which plays an essential role in the
stabilization and regulation of the BBSome [3, 4].
Other genes code for proteins with roles in the
localization and activation of BBSome (ARL6) or
BBSome entry into cilia (BBS17) or are associated
with the BBSome complex (BBS14) (Fig. 1 and Add-
itional file 1: Table S1). The functions of some of the
proteins are not fully understood. BBSome is a stable
protein complex that functions in the biogenesis and
maintenance of the primary cilium (Fig. 1), a struc-
ture that is ubiquitously expressed and highly
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conserved through evolution, and in modulating cil-
iary protein trafficking. Primary cilia serve as sensors
of the extracellular environment, they receive and
transduce signals from light, chemical, or mechanical
stimuli, [5] in addition they play a role in several sig-
nalling pathways important for development and
tissue homeostasis, their alteration results in abnor-
malities and multiorgan disfunctions. Many different
pathways have been linked to the primary cilium, in-
cluding Hedgehog, Wnt, Notch, Hippo, GPCR, PDGF,
mTOR, and TGF-beta [6].
For many years BBS was considered an autosomal
recessive disease, but recently evidence suggesting
complex digenic triallelic inheritance has been de-
scribed [7–9]. This could partly explain the large,
phenotypic heterogeneity found in BBS patients, both
inter- and intrafamilial [10].
There is currently no treatment for BBS, but some of
the co-morbidities can be managed. Precise identifica-
tion of the causative gene(s) is therefore a fundamental
step toward a personalized therapeutic approach and
management of genotype-related conditions [8, 11–17].
Thus, genetic analysis and accurate phenotyping are fun-
damental for stratifying patients and addressing appro-
priate therapy. In our study we analysed the mutation
spectrum in a cohort of 20 Italian patients with BBS, in-
vestigating the tri-allelic hypothesis and analysing
genotype-phenotype correlation.
Materials and methods
Patients
Twenty caucasian patients diagnosed in different hos-
pital across Italy with Bardet-Biedl syndrome were retro-
spectively included in the study. The mean (±SD) age
was 29 ± 17.1 (range 9–63) years and the male/female
ratio was 13:7. The mean age at diagnosis was 5.4 ± 7.2
(range 0–24) years. No consanguinity in their families
was reported [except for two probands that stated a
distant kinship]. Clinical diagnosis of BBS was made ac-
cording to the accepted criteria [1]. Genetic testing was
performed on germline DNA extracted from either saliva
or blood of the proband.
Mutation analysis
A custom-made oligonucleotide probe library was de-
signed to capture all coding exons and flanking exon/in-
tron boundaries (±15 bp) of 18 genes known to be
associated with Bardet-Biedl syndrome (Additional file 1:
Table S1 and Additional file 2: for protocol details).
DNA from the proband was analysed. Identified variants
with likely clinical significance (pathogenic, likely patho-
genic and of unknown significance according to the
ACMG guideline) [18] were confirmed by bidirectional
Sanger sequencing on a CEQ8800 Sequencer (Beckman
Coulter). Segregation in family members was performed
for variants identified in the proband in heterozygous
Fig. 1 Schematic representation of the cilium and intraflagellar transport. 1. transition zone; 2. basal body; 3. axoneme; 4. pericentriolar area. BBS-
chaperonin complex (BBS6, BBS10, BBS12) binds and stabilizes the BBS protein to form the BBSome (BBS1, BBS2, BBS4, BBS5, BBS7, BBS8, BBS9, BBS17,
BBS18). BBSome plays a critical role in the regulation of cilia composition and in intraflagellar trafficking. Indeed, transmembrane (TM) and periferal
membrane protein are transported in the cilium in a BBSome dependent manner. BBS3 triggers BBSome complex /cargo proteins interaction and their
transition across the control barrier (transition zone - BBS13, BBS14, BBS15) into the cilium. In bold, genes included in our NGS panel
Manara et al. Italian Journal of Pediatrics           (2019) 45:72 Page 2 of 8
state in order to confirm that the variants were in trans
(yes in column Seg in Table 1).
Statistical analysis
The relation between two class group variables was
assessed by Fisher exact test.
Results
The 20 patients with Bardet-Biedl syndrome enrolled in
this study were screened using a panel of 18 genes associ-
ated with the disease. We obtained the following results.
No variants could be found in eight patients whose char-
acteristics are described in Additional file 1: Table S3). We
defined the causal variants in 12 patients (60%) (Table 1);
5 patients were confirmed to have a compound heterozy-
gous variant in a BBS gene, while 7 patients where homo-
zygous for the causative variant. In four cases the
pathogenic variants were novel. We identified a novel
compound heterozygous variant in BBS1 c.1285dup
(p.(Arg429Profs*72); a likely pathogenic novel variant af-
fecting the conserved residue 354 in the functional do-
main of BBS2 (c.1062C >G; p.(Asn354Lys)); a pathogenic
new homozygous nucleotide change in BBS7 that leads to
a stop codon in position 255, c.763A > T, and a likely
pathogenic homozygous substitution c.1235G > T in
BBS6, leading to the change p.(Cys412Phe). The novel var-
iants were scored as pathogenic or likely pathogenic ac-
cording to Richards et al. classification [18]. Four of the 12
patients in which the causative gene had been identified,
also had potentially pathogenic variants in additional BBS
genes suggesting oligogenic inheritance and a possible
modifier effect. Three out of 4 patients presented variants
in two additional genes, while patient #6 presented a vari-
ant with unknown significance (VUS) in BBS1 in addition
to the “principal variants” in BBS12. Patient #4 presented
“principal mutations” in BBS2 and additional functional
polymorphism in BBS12 and a variant with unknown sig-
nificance in INPP5; patient #10 presented additionally to
Table 1 Bardet-Biedl syndrome patients with resolved genotype
Sex Seg Gene Ex/ int Nucleotide substitution Protein substitution Het/Homo Type Score
[18]
Ref RS MAF
1 M Yes BBS2 ex9 c.1015C > T p.(Arg339*) Het nonsense P [14] rs193922710 N/A
BBS2 ex9 c.1062C > G p.(Asn354Lys) Het missense P
2 M Yes BBS10 ex2 c.1091del p.(Asn364Thrfs*5) Het frameshift P [15] rs727503818 0.00005
BBS10 ex2 c.1677del p.(Tyr559*) Het nonsense P [4]
3 M BBS7 ex8 c.763A > T p.(Lys255*) Homo nonsense P
4 F BBS2 ex8 c.814C > T p.(Arg272*) Homo nonsense P [16, 17]
BBS12 ex2 c.116 T > C p.Ile39Thr Het missense fSNP [19] rs138036823
INPP5E ex1 c.532G > A p.Val178Met Het missense VUS
5 M BBS10 ex2 c.271dup p.(Cys91Leufs*5) Homo nonsense P [4, 20, 21] rs549625604 0.0007
6 F BBS12 ex2 c.1063C > T p.(Arg355*) Homo nonsense P [22] rs121918327 0.00002
BBS1 ex12 c.1016A > T p.(His339Leu) Het missense VUS
7 F Yes BBS10 ex2 c.641 T > A p.(Val214Glu) Homo missense P [23]
8 M Yes BBS10 ex2 c.1676dup p.(Tyr559*) Het nonsense P [24]
BBS10 ex2 c.962A > G p.(Tyr321Cys) Het missense LP [23]
9 F BBS12 ex2 c.1531_1539del p.(Gln511_Gln513del) Homo inframe del P [4, 19] rs752762669
10 M Yes BBS1 ex1 c.46A > T p.(Ser16Cys) Het missense LP rs772917364 0.008458
BBS1 ex13 c.1285dup p.(Arg429Profs*72) Het frameshift P
BBS10 ex2 c.765G > A p.(Met255Ile) Het missense LB [25] rs139658279
BBS14 ex10 c.829G > C p.(Glu277Gln) Het missense VUS [26] rs45502896
11 M Yes BBS4 int5 c.332 + 2_332 + 3insTT Het Insertion P [27] rs753360929
BBS4 ex13 c.1091C > A p.(Ala364Glu) Het missense P [28] rs28938468
BBS8 ex4 c.254A > G p.(Lys85Arg) Het missense VUS rs150880478
BBS2 ex9 c.986 T > C p.(Met329Thr) Het missense VUS rs201146063
12 F Yes BBS6 ex5 c.1235G > T p.(Cys412Phe) Homo missense LP
Never previously reported nucleotide substitutions are in bold
Abbreviations: M male, F female, seg segregation performed, ex exon, int intron, dup duplication, del deletion, ins insertion, het heterozygous, homo homozygous, P
pathogenic, LP likely pathogenic, LB likely benign, VUS variant unknown significance, fSNP functional single nucleotide polymorphism, Ref references, RS dbSNP
accession number, MAF minor allele frequency
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the principal variant in BBS1, variants in BBS10 and
BBS14, the first likely benign and the second with un-
known significance; patients #11 with compound hetero-
zygous variants in BBS4, presented additionally VUS in
BBS8 and BBS2. Unlikely, we cannot document any influ-
ence on the phenotype severity in patient carrying add-
itional variants in heterozygous state due to the small
cohort of patients analysed and to the fact that all the vari-
ants were missense and with an uncertain role in disease
manifestation.
In our cohort, we had a prevalence of patients har-
bouring genetic variants in BBS10 (N = 4), two patients
with variants in BBS2 and two in BBS12. The remaining
four patients had their causative pathogenic variants in
each of the following genes: BBS1, BBS4, BBS6, BBS7.
The clinical characteristics of positive patients are re-
ported in Table 2. Patients were predominantly males,
and all were clinically diagnosed during childhood or
adolescence (median age 21months). All patients with a
molecular diagnosis had polydactyly of one or both
hands or feet, in most cases hexadactyly of feet as well
as hands (N = 6) (Table 2 and Additional file 1: Table
S2). All patients had cone-rod dystrophy / retinitis pig-
mentosa (CRD/RP), except one who had myopia and
cataract (Additional file 1: Table S2), highlighting the
fact that clinical diagnosis of BBS is often made when
patients manifest ocular involvement. Other frequent
clinical characteristics in our cohort were intellectual
disability, hypogonadism, obesity and renal abnormalities
(Additional file 1: Table S2). The cohort of negative pa-
tients was not statistically significantly different from the
cohort of molecularly resolved patients (Additional file
1: Table S2).
Discussion
Bardet-Biedl syndrome, a ciliopathy with autosomal
recessive/oligogenic inheritance shows high clinical
variability and genetic heterogeneity. Although the
postaxial polydactyly is evident at birth, clinical diag-
nosis is usually made when patients complain of vis-
ual distress. Genetic testing can help to confirm the
diagnosis and enable prompt and effective clinical
management. The molecular characterization of
patients in addition can help to predict a grade of se-
verity and to identify carrier’s family members with
potential benefits of counselling. The targeted sequen-
cing also has the advantage of allowing the identifica-
tion of modifiers or genes with an epistatic effect that
can shed light on phenotypic variability between and
within families. Furthermore the molecular diagnosis
can be fundamental for personalized medicine, aiming
at the identification of patients potentially suitable for
enrolment in any appropriate clinical trial that may
become available in the future.
In this direction, recent advances in gene therapy and
personalized medicine have enabled significant advances
in the development of potential therapies for BBS pa-
tients, although the number of genes involved and the
variety of mutations identified in patients, often in the
same family, has increased the challenge faced by re-
searchers [29].
Our study was performed to increase the BBS muta-
tion spectrum in a cohort of 20 unrelated Italian patients
with BBS. Genetic diagnosis was obtained in 12/20 pa-
tients using a NGS targeted approach analysing simul-
taneously the 18 most frequently mutated genes
associated with BBS to increase the detection rate and
the understanding of the BBS phenotype through discov-
ery of additional mutations in BBS genes that could ex-
plain differences in phenotype severity.
The study revealed BBS10 gene mutations in a ma-
jority of our cohort (33%), in accordance with the
percentages already reported in the literature [4].
Interestingly, we found just one patient with variants
in BBS1, the most frequently detected gene in BBS
patients [4, 30–32].
We identified a novel variant in BBS1 patient #10
c.1285dup (p.(Arg429Profs*72)) defined as pathogenic
that segregates with phenotype together with c.46A > T
(p.(Ser16Cys), defined as likely pathogenic.
A new pathogenic variant in BBS2 affecting a con-
served residue in the functional domain of BBsome pro-
tein (c.1062C > G; p.(Asn354Lys)) was found in
compound heterozygous state in patient #1 together
with the known pathogenic variant p.(Arg339*). A new
homozygous nucleotide change in BBS7 that leads to a
stop codon in position 255, c.763A > T, was identified in
patient #3. BBS1, BBS2 and BBS7 share a partially over-
lapping portion of a functional domain, mutation of
which results in the same disease phenotype [30]. New
pathogenic variants of BBS2 and BBS7 lie in this portion.
The variant in BBS7 is noteworthy, since very few
Bardet-Biedl cases are reported in the literature. Indeed,
only 35 variants [33] in this gene are listed in the Hu-
man Gene Mutation Database (HGMD, https://portal.
biobase-international.com/cgi-bin/portal/login.cgi). A
homozygous substitution c.1235G > T in BBS6, leading
to p.(Cys412Phe), was also identified in an affected sib-
ling of proband #12. Interestingly, the clinical severity of
the phenotypes of the two siblings was different (Table
2), suggesting that these variants show intrafamilial vari-
able expressivity or that the patient’s genetic background
strongly influences phenotype.
Interestingly, four of the twelve patients in which
the causative gene had been identified, also had add-
itional variants in BBS genes suggesting oligogenic in-
heritance and a possible modifier effect. However, we
cannot document any influence on the phenotype
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severity in patient carrying additional variants in het-
erozygous state due to the small cohort of patients
analysed and to the fact that all the variants were
missense and with an uncertain role in disease mani-
festation. Our results are concordant with the results
obtained also by other authors: the impact of the
additional heterozygous variant remains elusive since
it is very difficult to determine the contribution of
the third allele to the phenotype. Available studies
compare different kind of mutations, with different
impact on the protein in small cohorts with high gen-
etic heterogeneity [32, 34]. Moreover, in our cohort,
we do not present family members with difference in
the genetic background that could help shed light on
the triallelic inheritance hypothesis [30].
In order to explore the function of different genes
involved in BBS we looked for possible correlations in
our cohort dividing patients with a molecular diagno-
sis with variants in BBSome genes or with variants in
BBSome chaperonin genes. The clinical phenotype
spectrum is wide (different type of mutations on dif-
ferent genes) and we did not observe any correlation
between characteristic of patients probably due to the
small number of patients analysed. This limits the
possibility to highlight genotype-phenotype correlation
with a statistical significance. Previous study have not
identified any correlation between individual geno-
types and phenotype [35, 36]. Interestingly, Billingsley
et al. stated that patients with mutations in BBS10 or
12 had a similar phenotype, supporting our sorting of
patients [33].
Characteristics such as obesity and intellectual impair-
ment or retinal degeneration affected patients with mu-
tations in genes of the BBSome or coding for BBSome
chaperonin with the same frequencies. Hypogonadism
(manifesting as genital anomalies in females and small
penis buried in adipose tissue with undescended testes
in males [11]) was more frequent in patients with vari-
ants in BBSome protein, whereas renal abnormalities
were mostly present in patients with variations in
BBSome chaperonin genes [12] (Table 3). Patients with
renal anomalies should therefore be screened mainly in
BBS10, BBS12, BBS6 and those with hypogonadism for
variants in BBSome genes. Clinicians should also closely
monitor patients harbouring mutations in BBS10,
BBS12, BBS6 to favour early detection of those with
renal anomalies, at risk of kidney failure and sudden
death.
In our cohort, hexadactyly was found in all patients
with a molecular diagnosis. Confirming the results of
Beales et al., polydactyly of the toes was more common
than that of the fingers in our cohort (11vs9), and both
feet more often had polydactyly than both hands (90% vs
66%) [13].
Conclusion
In conclusion, our results demonstrate that NGS
panels are a fast and effective way of obtaining high
diagnostic yields in diseases, such as BBS, caused by
mutations in many genes. They also provide informa-
tion on other mutant genes in addition to the
causative one. Genetic testing can provide insights
into the pathways involved in the disease and aid the
development of targeted therapy, which needs to
begin with the first eye symptoms, before extensive
photoreceptor damage. When feasible, NGS should be
considered the elective method of genetic testing to
confirm any hypothesis of tri-allelic inheritance. Our
results are further evidence that BBS is extremely het-
erogeneous: by describing four new variants we ex-
tend the mutational spectrum of known BBS genes
and contribute information on genotype-phenotype
correlations. Finally, the fact that 40% of our patients
did not have any mutation in the 18 known screened
genes, leads us to the consideration that although be-
ing the best available approach, targeted NGS do not
allow the detection of (i) deeply intronic variants that
could have an effect either on the splicing or expres-
sion of the genes; (ii) large gene rearrangements nor
(iv) the analysis of additional responsible loci yet to
be identified. In addition given the fact that there is a
significant overlap between clinical sign and mutated
genes within BBS and other ciliopathies such as
McKusick-Kaufman syndrome (MKKS; OMIM
604896), Alstrom syndrome (ALMS; OMIM 203800),
Meckel-Gruber syndrome (MKS; OMIM 249000,
603294, 607361, 611134), and Joubert syndrome
(JBTS; OMIM 213300, 608,091, 608629, 609583,
610688, 611560, 612291, 612285, 300804) we cannot
exclude that our negative patients presented variants
in genes more associated to the other syndromes and
that were not sequenced.
Table 3 Genotype/Phenotype correlations
BBSome BBSome chaperonin Fisher’s exact test
Obesity 3/5 (60%) 4/7 (57.1%) P = 1.0
Intellectual impairment 3/5 (60%) 4/7 (57.1%) P = 1.0
Renal abnormalities 1/5(20%) 4/7 (57.1%) P = 0.6
Hypogonadism 5/5 (100%) 2/7 (28.5%) P = 0.35
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Additional files
Additional file 1: Table S1. List of genes in the NGS panel. Table S2.
Distribution of BBS diagnostic criteria in patients with molecular
diagnosis. Table S3. Clinical manifestations of Bardet-Biedl syndrome pa-
tients with unresolved genotype. Abbreviations: M, male; F, female; yrs.,
years; mo, months; RP retinitis pigmentosa; CRD, cone-rod dystrophy; HM,
high myopia; O, obese; OW, overweight; N/K, not known. (DOCX 28 kb)
Additional file 2: Mutation analysis. The DNA probe set was designed
using specific Illumina DesignStudio online tool (https://designstudio.
illumina.com/). (DOCX 14 kb)
Abbreviations
BBS: Bardet-Biedl syndrome; CRD: Cone-rod dystrophy.; del: Deletion;
dup: Duplication; ex: Exon; F: Female; fSNP: Functional single nucleotide
polymorphism; het: Heterozygous; homo: Homozygous; ins: Insertion;
int: Intron; LB: Likely benign; LP: Likely pathogenic; M: Male; MAF: Minor allele
frequency; NGS: Next generation sequencing; P: Pathogenic; Ref: References;
RP: Retinitis pigmentosa; RS: dbSNP accession number; seg: Segregation
performed; VUS: Variant unknown significance
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